Search results for " Adjuvant"

showing 10 items of 245 documents

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-…

2019

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen. Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of sta…

Adult0301 basic medicineSubset AnalysisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAxillary lymph nodesmedicine.medical_treatmentTriple Negative Breast NeoplasmsDisease-Free SurvivalCapecitabineYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineCapecitabineNeoadjuvant therapyTriple-negative breast cancerAgedChemotherapyTaxanebusiness.industryHazard ratioMiddle AgedNeoadjuvant Therapy030104 developmental biologymedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalebusinessmedicine.drug
researchProduct

Validity of Laparoscopic Staging to Avoid Adjuvant Chemoradiation following Radical Surgery in Patients with Early Cervical Cancer

2012

<b><i>Purpose:</i></b> To determine the rate of unavoidable adjuvant chemoradiation (RCTX) due to histologic results after radical surgery in patients with early cervical cancer. <b><i>Patients and Methods:</i></b> Between May 2004 and July 2011, 448 consecutive patients diagnosed with invasive cervical cancer stage IA1 L1 to IIA underwent laparoscopic staging at the Department of Gynecology and Gynecologic Oncology at Charité Berlin. Only in patients without lymph node metastases (n = 394) on frozen section, radical operation was continued either by laparoscopic radical hysterectomy (n = 228) or by radical vaginal trachelectomy (n = 166). The…

AdultCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentUterine Cervical NeoplasmsRadical vaginal trachelectomyAdjuvant chemoradiationHysterectomyYoung AdultRisk FactorsEarly cervical cancermedicineHumansRadical hysterectomyProspective StudiesRadical HysterectomyRadical surgeryLaparoscopyProspective cohort studyAgedNeoplasm StagingAged 80 and overCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryGeneral surgeryChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryClinical trialOncologyLymphatic MetastasisAdjuvant chemoradiation; Early cervical cancer; Radical hysterectomyVaginaLymph Node ExcisionFemaleLaparoscopyRisk factorbusinessChemoradiotherapy
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.

2019

Background/aim Pineoblastoma of the adult age is an uncommon tumor with only 200 cases reported. A standardized approach for an optimal adjuvant strategy is currently lacking. The case presented herein also deals with the issue of central nervous system tumors in pregnancy. Case report A 21-year-old pregnant woman presented with massive hydrocephalus due to a mass in the pineal region detected with MRI. After positioning an urgent ventricular derivation, a cesarean section was performed. During a third ventriculocisternostomy, a biopsy revealed a pineoblastoma. After a maximal safe resection, postoperative craniospinal irradiation for a total dose of 36 Gy plus a sequential boost to the tum…

AdultCancer Researchmedicine.medical_specialtyVincristinePineal GlandCraniospinal IrradiationVentriculostomy03 medical and health sciences0302 clinical medicinePregnancyBiopsyMedicineHumansPineoblastomaPregnancymedicine.diagnostic_testbusiness.industryCesarean SectionGestational ageGeneral MedicineChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingHydrocephalusAdult PineoblastomaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologybusinessPinealomaPregnancy Complications Neoplasticmedicine.drugAnticancer research
researchProduct

Experiences of Patients With Breast Cancer of Participating in a Lifestyle Intervention Study While Receiving Adjuvant Chemotherapy

2017

Background Lifestyle interventions are suggested to reduce the symptom burden and comorbidities in patients with breast cancer and as an empowerment tool. However, undergoing chemotherapy is associated with low compliance to lifestyle recommendations. Importantly, few studies have documented the experiences of patients with breast cancer of participating in a comprehensive lifestyle intervention study while undergoing curative chemotherapy. Objective The aim of this study was to explore the experiences of patients with breast cancer of participating in an individualized comprehensive lifestyle intervention study focusing on diet, physical activity, mental stress management, and smoking cess…

AdultCounselingmedicine.medical_specialtyPalliative caremedicine.medical_treatmentmedia_common.quotation_subjectMEDLINEBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerAdaptation PsychologicalmedicineHumans030212 general & internal medicinePatient participationEmpowermentExerciseLife StyleQualitative ResearchAgedmedia_commonOncology (nursing)business.industryPalliative CareCancerMiddle Agedmedicine.diseaseOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFamily medicinePhysical therapyPatient ComplianceSmoking cessationFemalePatient ParticipationbusinessQualitative researchCancer Nursing
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune res…

2021

Significance Vaccines profit from the addition of adjuvants to better and more specifically initiate, amplify, and shape immune responses. Although the number of adjuvant candidates has steadily increased, peaking in the current SARS-CoV-2 pandemic, little is known about their inherent mode of action. Using human blood immune cells, we established a multilayer method to systematically assess the adjuvants’ effects on innate and adaptive immune cells. By employing a multiplex analysis with cells from 30 different donors, we determined important patterns of adjuvant function. Moreover, we demonstrate correlates of an antiviral immune response using a Toll-like receptor 7/8 ligand adjuvant and…

AdultMaleAdolescentT-LymphocytesMonophosphoryl Lipid ALipid Achemistry.chemical_compoundImmunology and InflammationImmune systemAdjuvants ImmunologicInterferonTLRmedicineHumansprimary human cellsAgedImmunity CellularToll-like receptorMultidisciplinarySARS-CoV-2ChemistryToll-Like ReceptorsImidazolesCOVID-19Dendritic CellsTLR7biochemical phenomena metabolism and nutritionBiological SciencesMiddle AgedCOVID-19 ; TLR ; primary human cells ; adjuvants ; mRNA vaccines420Cell biologymRNA vaccinesLipid AadjuvantsTLR4[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleResiquimodmedicine.drugProceedings of the National Academy of Sciences
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct